PT Pyridam Farma Tbk
PYFA
Rank in Stocks
#20946
PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the... PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the development, production, and distribution of a broad spectrum of health-related products. Its offerings encompass pharmaceuticals, antibiotics, essential vitamins, dietary supplements, and traditional herbal remedies. The company's operations are divided into two main segments: Pharmaceutical Products and Contract Manufacturing Services, and Medical Device Products. Within its medical device division, the firm provides a variety of instruments and consumables. These include clinical waste management items, collection swabs and tubes, innerbox DCA, KF94 masks, parafilm, PCR extraction kits and their accompanying machinery, specimen bags, sterile containers, and tube stoppers. Furthermore, PT Pyridam Farma markets a diverse collection of skincare products, such as Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel. Its pharmaceutical portfolio addresses numerous therapeutic areas, including digestive and metabolic health, blood and blood-forming organ conditions, cardiovascular disorders, dermatological ailments, genitourinary system and sex hormone regulation, systemic corticosteroids, systemic antibacterial treatments, sensory organ issues, as well as musculoskeletal, nervous, and respiratory system conditions. Beyond medicinal lines, the company also develops and sells dietary supplements and preventive consumer health items, notably energy drinks and various healthy ready-to-consume beverages. A key area of its strategic focus involves conducting extensive research and development in biotechnology, life sciences, and medical science. Established in 1976, PT Pyridam Farma Tbk is headquartered in Jakarta, Indonesia.
Share Price
$0.00670277
Last synced: 2026-11-10
Market Cap
$75.32M
Change (1 day)
2.54%
Change (1 year)
-78.82%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PT Pyridam Farma Tbk (PYFA)
Category
Healthcare
Number of shares outstanding for PT Pyridam Farma Tbk (PYFA)
Number of shares outstanding as of September 2026: 11.24B
According to PT Pyridam Farma Tbk's latest financial reports, its current number of shares outstanding is 11.24B. At the end of 2025 the company had 11.24B shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for PT Pyridam Farma Tbk (PYFA) from 2005 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 11.24B | 0.00% |
| 2025 | 11.24B | 32.38% |
| 2024 | 8.49B | 240.59% |
| 2023 | 2.49B | 0.00% |
| 2022 | 2.49B | 0.00% |
| 2021 | 2.49B | 0.00% |
| 2020 | 2.49B | 0.00% |
| 2019 | 2.49B | -6.85% |
| 2018 | 2.68B | 0.00% |
| 2017 | 2.68B | 0.00% |
| 2016 | 2.68B | 0.00% |
| 2015 | 2.68B | 0.00% |
| 2014 | 2.68B | 0.00% |
| 2013 | 2.68B | 0.00% |
| 2012 | 2.68B | 0.00% |
| 2011 | 2.68B | 0.00% |
| 2010 | 2.68B | 0.00% |
| 2009 | 2.68B | 0.00% |
| 2008 | 2.68B | 0.00% |
| 2007 | 2.68B | 0.00% |
| 2006 | 2.68B | 0.00% |
| 2005 | 2.68B | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 434.78M | -96.13% |
DE
|
|
| 434.78M | -96.13% |
DE
|
|
| 1.56B | -86.09% |
JP
|
|
| 233.66M | -97.92% |
CH
|
|
| 1.17B | -89.62% |
IL
|
Questions about PT Pyridam Farma Tbk's number of shares outstanding
What is PT Pyridam Farma Tbk's number of shares outstanding?
PT Pyridam Farma Tbk's number of shares outstanding is 11.24B, as of Sep 2026.
What was PT Pyridam Farma Tbk's number of shares outstanding in 2025?
In 2025, PT Pyridam Farma Tbk's number of shares outstanding was 11.24B, 32.38% more than in 2024 (8.49B).
How has PT Pyridam Farma Tbk's number of shares outstanding changed since 2020?
From 2020 to 2025, PT Pyridam Farma Tbk's number of shares outstanding went from 2.49B to 11.24B, an average growth of 35.15% a year.